1 Centre D'Investigation Clinique CIC 1436, Services de Pharmacologie Clinique Et Neurosciences, NS-Park/FCRIN Network, NeuroToul COEN Center, Université de Toulouse UPS, CHU de Toulouse, INSERM Toulouse, 37 Allées Jules Guesde, 31000, Toulouse, France. olivier.rascol@univ-tlse3.fr.
2 LN Pharma, Toulouse, France.
3 Unité de Recherche Clinique Et Epidémiologie, Département D'Information Médicale, Hôpital La Colombière, Montpellier, France.
4 Department of Neurology, NS-Park/FCRIN Network, Université de Nantes, CHU de Nantes, INSERM; CIC 1413, Nantes, France.
5 Department of Neurology, U 837, NS-Park/FCRIN Network, Université de Lille, CHU de Lille, INSERM, Lille, France.
6 Department of Neuroscience, University of Turin, Torino, Italy.
7 Service de Neurologie, NS-Park/FCRIN Network, CHU de Bordeaux, 33000, Bordeaux, France.
8 Institut Des Maladies Neurodégénératives, CNRS UMR 5293, Univ. de Bordeaux, 33000, Bordeaux, France.
9 Dept. Medicine, University of Otago, Christchurch, and New Zealand Brain Research Institute, Christchurch, New Zealand.
10 Centre D'Investigation Clinique CIC 1436, Services de Pharmacologie Clinique Et Neurosciences, NS-Park/FCRIN Network, NeuroToul COEN Center, Université de Toulouse UPS, CHU de Toulouse, INSERM Toulouse, 37 Allées Jules Guesde, 31000, Toulouse, France.
11 Biomedical Research Center, Interamerican Open University (CAECIHS-UAI), National Research Council (CONICET), Buenos Aires, Argentina.
12 Department of Physiology, School of Medicine, University of Buenos Aires (UBA), Buenos Aires, Argentina.
13 Faculty of Medical Sciences, Pontificia Universidad Católica Argentina (UCA), Buenos Aires, Argentina.